ImmunoScape
- Company typePrivate
- Founded2016
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingServices
ImmunoScape firmographics
Firmographics- Name
- ImmunoScape
- Legal name
- ImmunoScape Pte. Ltd.
- Website
- https://immunoscape.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
ImmunoScape industry classification
Industry- Product category
- Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industry
- Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)
Keywords
Where ImmunoScape is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices2 records
Markets served
ImmunoScape business model
Business model- GTM type
- B2B
- Offering type
- Services
Revenue model
- TCR-T Cell Therapy Development: Pre-revenue clinical-stage biotech developing TCR-based cancer immunotherapies. Revenue will be generated through eventual therapeutic product sales upon regulatory approval, along with potential milestone payments and royalties from licensing agreements.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
ImmunoScape product offering
Product offeringCore offering
ImmunoScape develops TCR-based cancer immunotherapies through its proprietary Seed-and-Boost platform, which combines engineered TCR-T cells with Immuno-STAT molecules to improve T cell expansion, persistence, and anti-tumor activity in solid tumors. The company's lead program, IS-001, targets WT1-positive solid tumors, and its Deep Immunomics technology underpins antigen and TCR discovery directly from patient-derived immune repertoires. ImmunoScape also extends its technology into partnered programs with pharmaceutical companies, including the CUE-100 series (CUE-102) with Cue Biopharma.
Product overview
ImmunoScape is a clinical-stage biotechnology company developing next-generation TCR-based cancer immunotherapies through its integrated platform approach. The company's core offering is the Seed and Boost™ Platform, which combines two key components: (1) IS-001, the lead program using WT1 TCR-T cells engineered via the Deep Immunomics Platform, and (2) CUE-102, a clinically validated Immuno-STAT® molecule (from the CUE-100 Series licensed from Cue Biopharma) that selectively expands and activates tumor-specific T-cells in-vivo. The Deep Immunomics Platform enables high-throughput discovery of potent TCRs, while the Immuno-STAT Platform provides the booster molecule technology for selective T-cell engagement and expansion. Additional offerings include the Cytographer® cloud-based bioinformatics platform for immune profiling data analysis.
Differentiator
Problem solved
Functional benefit
Products and services
- IS-001 IS-001 is ImmunoScape's lead TCR-T cell therapy candidate, designed to treat WT1-positive solid tumors by leveraging the company's Seed-and-Boost strategy to improve T cell expansion, persistence, and anti-tumor activity. It is intended for cancer patients with WT1-expressing solid tumors who have limited treatment options.
- CUE-100 Series (including CUE-102) The CUE-100 series comprises Cue Biopharma's Immuno-STAT molecules co-developed with ImmunoScape, including CUE-102, designed to modulate T cell function against cancer. These programs represent the commercial application of ImmunoScape's Immuno-STAT technology in partnership with Cue Biopharma.
Quantifiable outcome
- 100% survival in high tumor burden ovarian cancer model in preclinical studies
- +1 more outcomes
Companies that use ImmunoScape
Customer profileSegments1 record
Ideal customer profiles2 records
ImmunoScape technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ImmunoScape partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- NCI-Designated Comprehensive Cancer Center (U.S.)coreMOU to launch investigator-initiated clinical trial targeting WT1-positive solid tumors including ovarian, mesothelioma, pancreatic, and colorectal cancers. First patient dosing expected by September 2026.
- Cue BiopharmacoreExclusive collaboration and license agreement to advance novel Seed-and-Boost immunotherapy combining Cue Biopharma's Immuno-STAT (CUE-100 series) with ImmunoScape's proprietary TCRs. Cue Biopharma received $15 million upfront payment ($10M in Q4 2025, $5M in November 2026) plus a 40% equity stake in ImmunoScape. The partnership targets solid tumor cell therapy with IND-enabling studies on track for 2027 submission.
- ScaleReadycoreG-Rex Grant of $250,000 to support WT1-targeted TCR-T cell therapy development including process development, quality control, and IND-enabling studies with goal of FDA submission in 2026. Grant aided by Wilson Wolf Manufacturing and Bio-Techne.
- Singapore Experimental Drug Development Centre (EDDC)coreStrategic alliance formed in December 2023 to develop TCR-based bispecific molecules for solid tumors.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
ImmunoScape competitors and assessment
Company assessmentDirect peers
- Adaptimmune: Clinical-stage TCR-T cell therapy company with an FDA-approved solid tumor product (afami-cel for synovial sarcoma) and an MAGE-A4 franchise. Directly comparable to ImmunoScape as a TCR-T developer targeting solid tumor antigens with engineered T-cell receptors.
- Immatics: Clinical-stage TCR-based immunotherapy company developing engineered TCR-T cells (ACTengine) and TCR bispecifics against tumor-specific antigens including PRAME and MAGEA4/8, partnered with Bristol Myers Squibb. Directly comparable to ImmunoScape's TCR discovery + cell therapy platform approach.
- Cue Biopharma: Developer of the Immuno-STAT platform (CUE-100 series) that ImmunoScape has exclusively in-licensed for oncology. Cue holds 40% of ImmunoScape and shares the Seed-and-Boost program, making it simultaneously a partner and the closest comparable platform peer.
- Tessa Therapeutics: Clinical-stage cell therapy company developing TCR-T and CAR-T therapies for solid tumors, including HPV-associated cancers. Comparable in stage, modality (engineered TCR-T), and Singapore/Asia origins — ImmunoScape's VP of Discovery previously held a leadership role at Tessa.
Emerging players
- Tmunity Therapeutics: Cell therapy developer focused on engineered T cells (CAR-T and TCR-T) for solid tumors and autoimmune disease, founded out of the University of Pennsylvania. Led by Usman Azam (also on ImmunoScape's board) until its wind-down, making it a directly comparable TCR-T solid tumor play.
- TCR² Therapeutics (now part of Adaptimmune): Developed TRuC-T cell therapies targeting solid tumors using a novel TCR fusion construct. Directly comparable modality (engineered T-cell receptor therapy for solid tumors) and recently combined with Adaptimmune, the leading direct peer.
Broad incumbents
- Kite Pharma (a Gilead Company): Commercial-stage leader in cell therapy with approved CAR-T products (Yescarta, Tecartus) for hematologic malignancies. A broad incumbent in the engineered T-cell therapy space; Adrian Bot (now on ImmunoScape's board) previously served as Kite's CSO, providing direct strategic adjacency.
- Novartis: Delivered the first FDA-approved CAR-T therapy (Kymriah) and operates a major Cell and Gene Therapies unit previously headed by Usman Azam, who now sits on ImmunoScape's board. A broad incumbent with the most established cell therapy commercial infrastructure.
- Bristol Myers Squibb: Developer of Yervoy and Opdivo (immuno-oncology checkpoint inhibitors) and a partner of Immatics for TCR-based therapies. Comparable as a large pharma incumbent pursuing TCR-based solid tumor strategies via partnership and acquisition.
- AstraZeneca: Developer of Imfinzi (durvalumab), a checkpoint inhibitor broadly used across solid tumor indications. Rachel Humphrey, who led Imfinzi's clinical development, is now an ImmunoScape SAB member — making AstraZeneca a strategically adjacent incumbent in solid tumor immunotherapy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
ImmunoScape social profiles
Digital presenceImmunoScape financial estimates
Financial estimateRevenue estimate
Valuation estimate
ImmunoScape leadership team
Management profileNumber of profiles
ImmunoScape funding detail
Funding detailFunding overview
Funding rounds6 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ImmunoScape M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ImmunoScape
What does ImmunoScape do?
ImmunoScape develops TCR-based cancer immunotherapies through its proprietary Seed-and-Boost platform, which combines engineered TCR-T cells with Immuno-STAT molecules to improve T cell expansion, persistence, and anti-tumor activity in solid tumors. The company's lead program, IS-001, targets WT1-positive solid tumors, and its Deep Immunomics technology underpins antigen and TCR discovery directly from patient-derived immune repertoires. ImmunoScape also extends its technology into partnered programs with pharmaceutical companies, including the CUE-100 series (CUE-102) with Cue Biopharma.
Is ImmunoScape a public or private company?
ImmunoScape is a private company. It is classified as venture growth investor backed and is currently operating.
When was ImmunoScape founded?
ImmunoScape was founded in 2016. It employs 11 to 50 people.
Where is ImmunoScape based?
ImmunoScape is headquartered in Singapore, Singapore, in the Asia region.
How does ImmunoScape make money?
One revenue line is on record: TCR-T Cell Therapy Development.
Who are ImmunoScape's main competitors?
Direct peers on record are Adaptimmune, Immatics, Cue Biopharma and Tessa Therapeutics. Emerging players are Tmunity Therapeutics and TCR² Therapeutics (now part of Adaptimmune). Broad incumbents are Kite Pharma (a Gilead Company), Novartis, Bristol Myers Squibb and AstraZeneca.
Does ImmunoScape have an API?
No public API is recorded for ImmunoScape.
What industry is ImmunoScape in?
ImmunoScape's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 325414 and its SIC code is 2836.